Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer
Melina Peressini, Rosario García-Campelo, Bartomeu Massutí et al. · Clinical Cancer Research · 2024
PURPOSE: Transcriptomic subtyping holds promise for personalized therapy in extensive-stage small cell lung cancer (ES-SCLC). In this study, we aimed to assess intratumoral transcriptomic subtype diversity and to identify biomarkers of long-term chemoimmunotherapy benefit in human ES-SCLC. EXPERIMENTAL DESIGN: We analyzed tumor samples from 58 patients with ES-SCLC enrolled in two multicenter single-arm phase IIIb studies evaluating frontline chemoimmunotherapy in Spain: n = 32 from the IMfirst trial and n = 26 from the CANTABRICO trial. We used the GeoMx Digital Spatial Profiler system to perform multi-region transcriptomic analysis. For subtype classification, we performed hierarchical clustering using the relative expression of ASCL1 (SCLC-A), NEUROD1 (SCLC-N), POU2F3 (SCLC-P), and YAP1 (SCLC-Y). RESULTS: Subtype distribution was found to be similar between bothcohorts, except for SCLC-P, which was not identified in the CANTABRICO_DSP cohort. A total of 44% of the patients in both cohorts had tumors with multiple coexisting transcriptional subtypes. Transcriptional subtypes or subtype heterogeneity was not associated with outcomes. Most potential targets did not show subtype-specific expression. Consistently in both cohorts, tumors from patients with long-term benefit (time to progression ≥12 months) contained an IFNγ-dominated mRNA profile, including enhanced capacity for antigen presentation. Hypoxia and glycolytic pathways were associated with resistance to chemoimmunotherapy. CONCLUSIONS: This work suggests that intratumoral heterogeneity, inconsistent association with outcome, and unclear subtype-specific target expression might be significant challenges for subtype-based precision oncology in SCLC. Preexisting IFNγ-driven immunity and mitochondrial metabolism seem to be correlates of long-term efficacy in this study, although the absence of a chemotherapy control arm precludes concluding that these are predictive features specific for immunotherapy.
Cited by 16 works. doi:10.1158/1078-0432.ccr-24-0104
Authors
- Melina Peressini
- Rosario García-Campelo
- Bartomeu Massutí
- Cristina Martí
- Manuel Cobo
- Vanesa Gutiérrez
- Manuel Dómine
- José Fuentes
- Margarita Majem
- Javier de Castro
- Juan Felipe Cordoba
- María P. Diz
- Dolores Isla
- Emilio Esteban
- Enric Carcereny
- Laia Vilà
- Alberto Moreno-Vega
- Silverio Ros
- Amaia Moreno
- Francisco J. García
References
- First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
- Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.
- Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data
- Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
- Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
- Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities
- Multiplex digital spatial profiling of proteins and RNA in fixed tissue
- SCLC Subtypes Defined by ASCL1, NEUROD1, POU2F3, and YAP1: A Comprehensive Immunohistochemical and Histopathologic Characterization